Abou-Saleh MT, Foley S. Prevalence and incidence of hepatitis C in drug users: A review. Addictive Disorders & Their Treatment. 2008;7(4):190–198.

Alberti A, Vario A, Ferrari A, Pistis R. Review article: Chronic hepatitis C—Natural history and cofactors. Alimentary Pharmacology and Therapeutics. 2005;22(Suppl 2):74–78. [PubMed: 16225479]

Alter MJ, Krusran-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine. 1999;341(8):556–562. [PubMed: 10451460]

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: Author; 2000. text revision.

American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington, VA: Author; 2010. Retrieved March 4, 2011, from http://www​.psych.org/guidelines/mdd2010.

Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al. Alcohol use and treatment of hepatitis C virus: Results of a national multicenter study. Gastroenterology. 2006;130(6):1607–1616. [PubMed: 16697724]

Astone JM, Strauss SM, Hagan H, Des Jarlais DC. Outpatient drug treatment program directors’ hepatitis C-related beliefs and their relationship to the provision of HCV services. American Journal of Drug and Alcohol Abuse. 2004;30(4):783–797. [PubMed: 15624549]

Astone JM, Strauss SM, Munoz-Plaza C, Hagan H, Des Jarlais DC. Providing support to drug users infected with hepatitis C: The role of methadone maintenance treatment staff. Journal of Maintenance in the Addictions. 2005;3(1):33–46.

Astone JM, Strauss SM, Vassilev ZP, Des Jarlais DC. Provision of hepatitis C education in a nationwide sample of drug treatment programs. Drug Education. 2003;33(1):107–117. [PubMed: 12773028]

Astone-Twerell JM, Strauss SM, Hagan H, Des Jarlais DC. Drug treatment programs’ HCV service delivery to their HCV positive patients. Addiction Research & Theory. 2006;14(3):289–302.

Astone-Twerell JM, Strauss SM, Munoz-Plaza C. Stigma: Hepatitis C and drug abuse. HCV Advocate Medical Writer’s Circle. 2006. Retrieved March 4, 2011, from http://www​.hcvadvocate​.org/hcsp/articles/Stigma.html.

Backmund M, Meyer K, Edlin BR. Infrequent Reinfection after Successful Treatment for Hepatitis C Virus Infection in Injection Drug Users. Clinical Infectious Diseases. 2004;39(10):1540–1543. [PMC free article: PMC1510898] [PubMed: 15546094]

Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Hepatitis C virus infection and injection drug users: Prevention, risk factors, and treatment. Clinical Infectious Diseases. 2005;40(Suppl 5):S330–S335. [PubMed: 15768343]

Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection [review] Gastroenterology. 2010;139(6):1865–1876. [PMC free article: PMC3072961] [PubMed: 20950615]

Bart G, Piccolo P, Zhang L, Jacobson I, Schaefer RA, Kreek MJ, et al. Markers for hepatitis A, B and C in methadone maintained patients: An unexpectedly high co-infection with silent hepatitis B. Addiction. 2008;103(4):681–686. [PMC free article: PMC3810150] [PubMed: 18339114]

Belfiori B, Ciliegi P, Chiodera A, Bacosi D, Tosti A, Baldelli F, et al. Peginterferon plus ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Digestive and Liver Disease. 2009;41(4):303–307. [PubMed: 18938116]

Bell BP, Kruszon-Moran D, Shapiro CN, Lambert SB, McQuillan GM, Margolis HS. Hepatitis A virus infection in the United States: Serologic results from the Third National Health and Nutrition Examination Survey. Vaccine. 2005;23(50):5798–5806. [PubMed: 16307834]

Berenguer M, Palau A, Fernandez A, Benlloch S, Aguilera V, Prieto M, et al. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C. Liver Transplantation. 2006;12(7):1067–1076. [PubMed: 16622844]

Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: Interactions, outcomes, and implications. Journal of Clinical Gastroenterology. 2003;36(3):242–252. [PubMed: 12590237]

Brener L, Von Hippel W, Kippax S. Prejudice among health care workers toward injecting drug users with hepatitis C: Does greater contact lead to less prejudice? International Journal of Drug Policy. 2007;18(5):381–387. [PubMed: 17854726]

Butt AA, Wagener M, Shakil AO, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. Journal of Viral Hepatitis. 2005;12:81–85. [PubMed: 15655052]

Cacopardo B, Nunnari G, Nigro L. Clearance of HCV RNA following acute hepatitis A superinfection. Digestive and Liver Disease. 2008;41(5):371–374. [PubMed: 18182335]

Carey JD, Perlman C. Knowledge of hepatitis among active drug injectors at a syringe exchange program. Journal of Substance Abuse Treatment. 2005;29(1):47–53. [PubMed: 15979531]

Case Management Society of America. Case management adherence guidelines: Version 2.0. Little Rock, AR: Author; 2006.

Castera L, Constant A, Bernard PH, de Ledinghen V, Couzigou P. Lifestyle changes and beliefs regarding disease severity in patients with chronic hepatitis C. Journal of Viral Hepatitis. 2006;13:482–488. [PubMed: 16792542]

Center for Substance Abuse Treatment. Comprehensive case management for substance abuse treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1998. (Treatment Improvement Protocol (TIP) Series 27). HHS Publication No. (SMA) 98–3222.

Center for Substance Abuse Treatment. Enhancing motivation for change in substance abuse treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1999. (Treatment Improvement Protocol (TIP) Series 35). HHS Publication No. (SMA) 99–3354.

Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004. (Treatment Improvement Protocol (TIP) Series 40). HHS Publication No. (SMA) 04–3939.

Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005. (Treatment Improvement Protocol (TIP) Series 43). HHS Publication No. (SMA) 05–4048.

Center for Substance Abuse Treatment. Enhancing motivation for change inservice training. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006. HHS Publication No. (SMA) 06–4190.

Center for Substance Abuse Treatment. Implementing change in substance abuse treatment programs. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009. (Technical Assistance Publication (TAP) Series 31). HHS Publication No. (SMA) 09–4377.

Center for Substance Abuse Treatment. Addressing suicidal thoughts and behaviors in substance abuse treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2009. (Treatment Improvement Protocol (TIP) Series 50). HHS Publication No. (SMA) 09–4381.

Centers for Disease Control and Prevention. Hepatitis B FAQs for the public. Atlanta: Author; 2009. Retrieved June 7, 2011, from http://www​.cdc.gov/hepatitis/B/bFAQ.htm.

Centers for Disease Control and Prevention. Recommended adult immunization schedule—United States, 2010. Morbidity and Mortality Weekly Report. 2010;59(SS-1):1–4. [PubMed: 20075837]

Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2008. Morbidity and Mortality Weekly Report. 2010;58(33):921–926. [PubMed: 19713881]

Centers for Disease Control and Prevention. The ABCs of hepatitis. Atlanta: Author; 2010. Retrieved March 4, 2011, from http://www​.cdc.gov/hepatitis​/Resources/Professionals​/PDFs/ABCTable.pdf.

Chainuvati S, Khalid SK, Kancir S, Shea M, Edwards J, Sernyak M, et al. Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. Journal of Viral Hepatitis. 2006;13(4):235–241. [PubMed: 16611189]

Chen H, Cantrell CR. Prevalence and factors associated with self-reported vaccination rates among US adults at high risk of vaccine-preventable hepatitis. Current Medical Research Opinion. 2006;22(12):2489–2496. [PubMed: 17257463]

Cherner M, Letendre S, Heaton RK, Durelle J, Marquie-Beck J, Gragg B, et al. Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology. 2005;64(8):1343–1347. [PubMed: 15851720]

Conjeevaram H, Fried M, Jeffers L, Terrault N, Wiley-Lucas T, Afdhal N, et al. Peginterferon and ribavirin treatment in African American patients and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131(2):470–477. [PubMed: 16890601]

Conrad S, Garrett LE, Cooksley WG, Dunne MP, MacDonald GA. Living with chronic hepatitis C means you just haven’t got a normal life any more. Chronic Illness. 2006;2(2):121–131. [PubMed: 17175655]

Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus co-infection. Annals of Clinical Microbiology and Antimicrobials. 2005;13(4):13. [PMC free article: PMC1224851] [PubMed: 16159399]

Crowcroft NS. Hepatitis A virus infections in injecting drug users. Communicable Disease and Public Health. 2003;6(2):82–84. [PubMed: 12889283]

Dalgard O. Follow-up studies of treatment for hepatitis C virus infection among injection drug users. Clinical Infectious Disease. 2005;40(Suppl 5):S336–S338. [PubMed: 15768344]

Dalgard O, Bjøro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al. Treatment of chronic hepatitis C in injection drug users: 5 years’ follow-up. European Addiction Research. 2002;8(1):45–49. [PubMed: 11818693]

Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis—United States, 2007. Morbidity and Mortality Weekly Report. 2009;58(SS03):1–27. [PubMed: 19478727]

Delwaide J, Bourgeois N, Colle I, Robaeys G. Risk factors for hepatitis C: Past, present and future. Acta Gastroenterologica Belgica. 2002;65(2):87–89. [PubMed: 12148445]

Dieticians of Canada. Hepatitis C: Nutrition care. Canadian guidelines for health care providers. Canadian Journal of Dietetic Practice and Research. 2003;64(3):139–141. [PubMed: 12959661]

Evon DM, Verma A, Dougherty KA, Batey B, Russo M, Zacks S, et al. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Digestive Diseases and Sciences. 2007;52(11):3251–3258. [PubMed: 17394072]

Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes. 1993;6(6):602–610. [PubMed: 8098752]

Fabris P, Tositti G, Giordani MT, Baldo V, Pignattari E, Cantons S, et al. Assessing patients’ understanding of hepatitis C virus infection and its impact on their lifestyle. Alimentary Pharmacology and Therapeutics. 2006;23(8):1161–1170. [PubMed: 16611277]

Felsen UR, Fishbein DA, Litwin AH. Low rates of hepatitis A and B vaccination in patients with chronic hepatitis C at an urban methadone maintenance program. Journal of Addictive Diseases. 2010;29(4):461–5. [PMC free article: PMC2982770] [PubMed: 20924882]

Fireman M, Indest DW, Blackwell A, Whitehead AJ, Hauser P. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): The importance of routine mental health screening as a component of a comanagement model of care. Clinical Infectious Diseases. 2005;40(Suppl 5):S286–S291. [PubMed: 15768336]

Franciscus A, Highleyman L, Kukka C. Hepatitis A: What you need to know. San Francisco: Hepatitis C Support Project; 2007. HCSP fact sheet.

Freedman K, Nathanson J. Interferon-based hepatitis C treatment in patients with preexisting severe mental illness and substance use disorders. Expert Review of Anti-infective Therapy. 2009;7(3):363–376. [PubMed: 19344248]

Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. American Journal of Gastroenterology. 2001;96(1):179–183. [PubMed: 11197250]

Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency and human T-lymphotropic viruses. American Journal of Public Health. 1996;86(5):655–661. [PMC free article: PMC1380472] [PubMed: 8629715]

Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: An update, American Association for the Study of Liver Diseases (AASLD) practice guidelines. Hepatology. 2009;49(4):1335–1374. [PMC free article: PMC7477893] [PubMed: 19330875]

Gish RG, Afdhal NH, Dieterich DT, Reddy KJ. Management of hepatitis C virus in special populations: Patient and treatment considerations. Clinical Gastroenterology and Hepatology. 2005;3(4):311–318. [PubMed: 15822034]

Goldsmith J, Hauser P. Psychiatric issues in patients with hepatitis C. Psychiatric Annals. 2003;33(3):57–60.

Guadagnino V, Trotta MP, Carioti J, Caroleo B, Antinori A. Does depression symptomatology affect medication compliance during the first weeks of anti-HCV therapy in intravenous drug users? Digestive and Liver Disease. 2006;38(2):119–124. [PubMed: 16297672]

Guadagnino V, Trotta MP, Montesano F, Babudieri S, Caroleo B, Armignacco O, et al. Effectiveness of a multi-disciplinary standardized management model in the treatment of chronic hepatitis C in drug addicts engaged in detoxification programmes. Addiction. 2007;102(3):423–431. [PubMed: 17298650]

Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, et al. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Report. 2006;121(6):710–719. [PMC free article: PMC1781913] [PubMed: 17278406]

Hagan H, Strauss SM, Astone JM, Des Jarlais DC. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection. Clinical Infectious Diseases. 2005;40(Suppl 5):S297–S303. [PubMed: 15768338]

Hagedorn H, Dieperink E, Dingmann D, Durfee J, Ho SB, Isenhart C, et al. Integrating hepatitis prevention services into a substance use disorder clinic. Journal of Substance Abuse Treatment. 2007;32(4):391–398. [PubMed: 17481462]

Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendation of the International AIDS Society—USA Panel. JAMA. 2008;300(5):555–570. [PubMed: 18677028]

Heathcote J, Main J. Treatment of hepatitis C. Journal of Viral Hepatitis. 2005;12(3):223–235. [PubMed: 15850462]

Hepatitis C Support Project. Living with hepatitis C. San Francisco: Author; 2006. Retrieved March 4, 2011, from http://www​.hcvadvocate​.org/community/stories/Brian.pdf.

Hepatitis C Support Project. Living with hepatitis C. San Francisco: Author; 2007. Retrieved March 4, 2011, from http://www​.hcvadvocate​.org/community/stories/Kathleen.pdf.

Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42(1):63–71. [PubMed: 15892090]

Huckans M, Mitchell A, Pavawalla S. The influence of antiviral therapy on psychiatric symptoms among patients with hepatitis C and schizophrenia. Antiviral Therapy. 2010;15(1):111–119. [PMC free article: PMC2998439] [PubMed: 20167997]

Ida S, Tachikawa N, Nakajima A, Daikoku M, Yano M, Kikuchi Y, et al. Influence of human immunodeficiency virus type I infection on acute hepatitis A infection. Clinical Infectious Diseases. 2002;34(3):379–385. [PubMed: 11774086]

Institute of Medicine. Hepatitis and liver cancer: A national strategy for prevention and control of hepatitis B and C. Washington, DC: The National Academies Press; 2010. [PubMed: 25032367]

Klevens RM, Miller JT, Iqbal K, Thomas A, Rizzo EM, Hanson H, et al. The evolving epidemiology of hepatitis A in the United States: incidence and molecular epidemiology from population-based surveillance, 2005–7. Archives of Internal Medicine. 2010;170(20):1811–1818. [PubMed: 21059974]

Kresina TF, Bruce RD, Cargill VA, Cheever LW. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clinical Infectious Diseases. 2005;41(Suppl 1):S583–S588. [PubMed: 16265621]

Kresina TF, Sylvestre D, Seeff L, Litwin AB, Hoffman K, Lubran R, et al. Hepatitis infection in the treatment of opioid dependence and abuse. Substance Abuse: Research and Treatment. 2008;1:15–61. [PMC free article: PMC4395041] [PubMed: 25977607]

Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 2002;97(10):1289–1294. [PubMed: 12359033]

Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus–positive hemophiliacs and should be treated as an opportunistic infection. Journal of Infectious Diseases. 1999;179(5):1254–1258. [PubMed: 10191232]

Litwin AH, Soloway I, Gourevitch MN. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: Challenges and opportunities. Clinical Infectious Diseases. 2005;40(Suppl 5):S339–S345. [PubMed: 15768345]

Lok AS, McMahon BJ. American Association for the Study of Liver Diseases practice guidelines: Chronic hepatitis B: Update 2009. 2009. Retrieved March 4, 2011, from http://www​.aasld.org​/practiceguidelines/Documents​/Bookmarked​%20Practice%20Guidelines​/Chronic_Hep_B_Update_2009​%208_24_2009.pdf. [PubMed: 19714720]

Luetkemeyer A. HIV InSite Knowledge Base Chapter. University of California; San Francisco: 2010. Hepatitis B and HIV coinfection. Retrieved May 17, 2011, from http://hivinsite​.ucsf​.edu/InSite?page=kb-05-03-04#S3X.

Lum PJ, Hahn JA, Shafer KP, Evans JL, Davidson PJ, Stein E, et al. Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. Journal of Viral Hepatitis. 2008;15(3):229–236. [PubMed: 18233994]

Macias J, Palacios RB, Claro E, Vargas J, Vergara S, Mira JA, et al. High prevalence of hepatitis C virus infection among noninjecting drug users: Association with sharing the inhalation implements of crack. Liver International. 2008;28(6):781–786. [PubMed: 18312289]

Martin-Santos R, Diez-Quevedo C, Castellvi P, Navines R, Miquel M, Masnou H, et al. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology and Therapeutics. 2008;27(3):257–265. [PubMed: 17988237]

Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology. 2004;40(1):120–124. [PubMed: 15239094]

Maxwell S, Shinderman MS, Miner A, Bennet A. Correlation between hepatitis C serostatus and methadone dose requirement in 1,163 methadone-maintained patients. Heroin Addiction and Related Clinical Problems. 2002;4(2):5–10.

McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. American Journal on Addictions. 2009;19(1):4–16. [PMC free article: PMC3334287] [PubMed: 20132117]

McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. New England Journal of Medicine. 2009;360(18):1827–1838. [PubMed: 19403902]

McHutchison JG, Shiffman ML, Gordon SC, Lindsay KL, Morgan T, Norkrans G, et al. Sustained virologic response to interferon-alfa-2b +/− ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow up (abstract #744), 41st Annual Meeting of the European Association for the Study of the Liver. Journal of Hepatology. 2006;44(Suppl 2):S275.

Munoz-Plaza CE, Strauss SM, Astone JM, Des Jarlais DC, Hagan H. Drug treatment programs as sites of opportunity for the delivery of hepatitis C prevention education: Client and staff perspectives. Journal of Drug Issues. 2004;34(4):861–878.

Munoz-Plaza CE, Strauss SM, Astone JM, Des Jarlais DC, Hagan H. HCV (hepatitis C virus) pre-test and post-test counseling services at drug treatment programs: Missed opportunities for primary prevention. Contemporary Drug Problems. 2005;32:655–675.

Munoz-Plaza CE, Strauss SM, Astone-Twerell JM, Des Jarlais DC, Hagan H. Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs. Journal of Psychoactive Drugs. 2006;38(3):233–241. [PubMed: 17165366]

National Alliance of State and Territorial AIDS Directors. Viral hepatitis and HIV/AIDS integration: A resource guide for HIV/AIDS programs. Washington, DC: Author; 2005. Retrieved March 4, 2011, from http://www​.nastad.org​/Docs/highlight/200638_VHEP​%20Resource%20Guide.pdf.

National Center for Complementary and Alternative Medicine. CAM and hepatitis: A focus on herbal supplements. Bethesda, MD: Author; 2008. Retrieved March 4, 2011, from http://nccam​.nih.gov​/health/hepatitisc/hepatitisc.pdf.

National Institutes of Health. Management of hepatitis C: 2002, Consensus conference statement. Bethesda, MD: Author; 2002. Retrieved March 4, 2011, from http://consensus​.nih​.gov/2002/2002HepatitisC2002116html.htm.

National Institute of Mental Health. Mental health medications. Bethesda, MD: Author; 2008. NIH Publication No. 08-3929.

New York State Department of Health. Clinical guidelines for the medical management of hepatitis C. Albany, NY: Author; 2005. Retrieved March 4, 2011, from http://www​.health.state​.ny.us/diseases/communicable​/hepatitis/guidelines.

New York State Department of Health. HCV: What you need to know about hepatitis C. Albany, NY: Author; 2005. Retrieved March 4, 2011, from http://www​.health.state​.ny.us/diseases/communicable​/hepatitis​/hepc_needtoknow_stories.htm.

Office of Applied Studies. National Survey of Substance Abuse Treatment Services: 2007, Data on substance abuse treatment facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2007. (DASIS Series: S-44 HHS). Publication No (SMA) 08-4348.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2011. Retrieved March 4, 2011, from http://www​.aidsinfo.nih​.gov/ContentFiles​/AdultandAdolescentGL.pdf.

Paterson BL, Backmund M, Hirsch G, Yim C. The depiction of stigmatization in research about hepatitis C. International Journal of Drug Policy. 2007;18(5):364–373. [PubMed: 17854724]

Physicians’ Desk Reference 2010. 64th ed. Montvale, NJ: PDR Network, LLC; 2009.

Pol S, Lamorthe B, Thi NT, Thiers V, Carnot F, Zylberberg H, et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. Journal of Hepatology. 1998;28(6):945–950. [PubMed: 9672168]

Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Bruno S, et al. Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine. 2011;364(13):1195–1206. [PMC free article: PMC3766849] [PubMed: 21449783]

Quaglio G, Lugoboni F, Messelani P, Des Jarlais D, Lechi A. Hepatitis vaccination among drug users. Vaccine. 2006;24(15):2702–2709. [PubMed: 16436307]

Robaeys G, Buntinx F. Treatment of hepatitis C viral infections in substance abusers. Acta Gastro-Enterologica Belgica. 2005;68:55–67. [PubMed: 15832589]

Robaeys G, Van Vlierberghe H, Mathei C, Van Ranst M, Buntinx F. Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes. European Journal of Gastroenterology and Hepatology. 2006;18(2):159–166. [PubMed: 16394797]

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49(3):1017–1044. [PubMed: 19243014]

Rockstroh JK, Spengler U. HIV and hepatitis C virus co-infection. Lancet Infectious Diseases. 2004;4(7):437–444. [PubMed: 15219554]

Rodriguez-Mendez ML, Gonzalez-Quintela A, Aguilera A, Barrio E. Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. The American Journal of Gastroenterology. 2000;95(5):1316–1322. [PubMed: 10811346]

Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Harnzeh FM, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. New England Journal of Medicine. 2009;360(3):257–267. [PubMed: 19144941]

Rosenberg SD, Goodman LA, Oshe FC, Swartz MS, Essock SM, Butterfield MI, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. American Journal of Public Health. 2001;91(1):31–37. [PMC free article: PMC1446494] [PubMed: 11189820]

Rosenberg SD, Swanson JW, Wolford GL, Osher FC, Swartz MS, Essock SM, et al. The five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatric Services. 2003;54(6):827–835. [PubMed: 12773596]

Samet JH, Saitz R, Larson MJ. A case for enhanced linkage of substance abusers to primary medical care. Substance Abuse. 1996;17(4):181–199.

Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction. 2004;99(9):1167–1175. [PubMed: 15317637]

Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in difficult-to-treat psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology. 2007;46(4):957–959. [PubMed: 17668880]

Schaefer M, Mauss S. Hepatitis C treatment in patients with drug addiction: Clinical management of interferon-alpha-associated psychiatric side effects. Current Drug Abuse Reviews. 2008;1(2):177–187. [PubMed: 19630716]

Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N, et al. Adherence and mental side effects during hepatitis C treatment with interferon alpha and ribavirin in psychiatric risk groups. Hepatology. 2003;37(2):443–451. [PubMed: 12540795]

Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, et al. Hepatitis B in patients with HIV infection: Relationship to AIDS and patient survival. Annals of Internal Medicine. 1992;117:837–838. [PubMed: 1416559]

Scheft H, Fontenette DC. Psychiatric barriers to readiness for treatment for hepatitis C virus (HCV) infection among injection drug users: Clinical experience of an addiction psychiatrist in the HIV–HCV coinfection clinic of a public health hospital. Clinical Infectious Diseases. 2005;40(Suppl 5):S292–S296. [PubMed: 15768337]

Sherman KE. New paradigms in the management of hepatitis C virus co-infections. Nature Clinical Practice Gastroenterology and Hepatology. 2007;4(Suppl 1):S10–S16. [PubMed: 17235280]

Silberbogen AK, Mori DL, Sogg S. The structured interview for the treatment of the hepatitis C virus (SIT-HCV). Journal of Clinical Psychology in Medical Settings. 2005;12(1):57–69.

Sorensen JL, Masson CL, Perlman DC. HIV/hepatitis prevention in drug abuse treatment programs: Guidance from research. NIDA Science & Practice Perspectives. 2002;1(1):4. [PMC free article: PMC2851052] [PubMed: 18567957]

Straits-Tröster KA, Sloan KL, Dominitz JA. Psychiatric and substance use disorder comorbidity with hepatitis C. Psychiatric Annals. 2003;33:362–368.

Strauss SM, Astone JM, Des Jarlais DC, Hagan H. Integrating hepatitis C services into existing HIV services: The experiences of a sample of U.S. drug treatment units. AIDS Patient Care and Standards. 2005;19(2):78–88. [PubMed: 15716639]

Strauss SM, Astone JM, Hagan H, Des Jarlais DC. Content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units. Journal of Urban Health. 2004;81(1):38–47. [PMC free article: PMC3456136] [PubMed: 15047782]

Strauss SM, Astone JM, Munoz-Plaza C, Hagan H, Des Jarlais D. Residential substance user treatment programs as venues for HCV pharmacological treatment: Client and staff perspectives. Substance Use & Misuse. 2005;40(12):1811–1829. [PubMed: 16419558]

Strauss SM, Astone-Twerell J, Munoz-Plaza CE, Des Jarlais DC, Gwadz M, Hagan H. Drug treatment program patients’ hepatitis C virus (HCV) education needs and their use of available HCV education services. BMC Health Services Research. 2007;7:39. [PMC free article: PMC1831471] [PubMed: 17346346]

Strauss SM, Astone-Twerell JM, Munoz-Plaza C, Des Jarlais DC, Gwadz M, Hagan H, et al. Hepatitis C knowledge among staff in U.S. drug treatment programs. Journal of Drug Education. 2006;36(2):141–158. [PubMed: 17153514]

Strauss SM, Munoz-Plaza C, Tiburcio NJ, Astone-Twerell J, Des Jarlais DC, Gwadz M, et al. Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. Journal of Drug Issues. 2008;38(4):1161–1185.

Stringari-Murray S, Clayton A, Chang J. A model for integrating hepatitis C services into an HIV/AIDS program. Journal of the Association of Nurses in AIDS Care. 2003;14(Suppl 5):S95–S107. [PubMed: 14571564]

Substance Abuse and Mental Health Services Administration. Estimation methodology for adults with serious mental illness (SMI). Federal Register. 1999 June 24;64(121):33890–33897. 1999. Retrieved March 4, 2011, from http://www​.gpo.gov/fdsys​/pkg/FR-1999-06-24/html/99-15377.htm.

Sulkowski MS. Viral hepatitis and HIV coinfection. Journal of Hepatology. 2008;48(2):353–367. [PubMed: 18155314]

Swain MG, Lai MY, Shiffman ML, Cooksley WG, Abergel A, Lin A, et al. Sustained virologic response resulting from treatment with peginterferon alfa-2a alone or in combination with ribavirin is durable and constitutes a cure: An ongoing 5-year follow-up [abstract #444]. Gastroenterology; Abstracts of Digestive Disease Week and the 108th Annual Meeting of the American Gastroenterological Association Institute; May 19–24, 2007; Washington, DC. Apr, 2007. p. A741.

Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. European Journal of Gastroenterology and Hepatology. 2007;19(9):741–747. [PubMed: 17700258]

Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. Journal of Substance Abuse Treatment. 2005;29:159–165. [PubMed: 16183464]

Sylvestre DL, Zweben JE. Integrating HCV services for drug users: A model to improve engagement and outcomes. International Journal of Drug Policy. 2007;18(5):406–410. [PubMed: 17854729]

Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;46(3):1497–1505. [PubMed: 20635398]

Tseng FC, O’Brien TR, Zhang M, Kral AH, Ortiz-Conde BA, Lorvick J, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology. 2007;46(3):666–671. [PMC free article: PMC4751875] [PubMed: 17657818]

Umbricht-Schneiter A, Ginn DH, Pabst KM, Bigelow GE. Providing medical care to methadone clinic patients: Referral vs. on-site care. American Journal of Public Health. 1994;84(2):207–210. [PMC free article: PMC1615007] [PubMed: 8296941]

U.S. Department of Health & Human Services. Combating the silent epidemic of viral hepatitis: Action plan for the prevention, care & treatment of viral hepatitis. Washington, DC: Author; 2011. Retrieved May 13, 2011, from http://www​.hhs.gov/ash​/initiatives/hepatitis​/actionplan_viralhepatitis2011.pdf.

U.S. Department of Veterans Affairs. Challenges for people in drug and alcohol recovery. 2004. Retrieved March 4, 2011, from http://www​.hepatitis​.va.gov/vahep?page=treat-14-04.

U.S. Department of Veterans Affairs. Managing side effects of hepatitis C treatment. 2007. Retrieved March 22, 2011, from http://www​.hepatitis​.va.gov/pdf/treatment-side-effects.pdf.

U.S. Department of Veterans Affairs. Alternative and complementary therapies. 2011. Retrieved March 22, 2011, from http://www​.hepatitis​.va.gov/patient/alternative-therapies​/index.asp.

U.S. Food and Drug Administration, Consumer Health Information Update. Understanding antidepressant medications. 2009. Retrieved July 29, 2011, from http://www​.fda.gov/ForConsumers​/ConsumerUpdates/ucm095980​.htm.

U.S. Food and Drug Administration. Prescribing information for Twinrix (hepatitis A & hepatitis B [recombinant] vaccine). 2010. Retrieved July 6, 2011, from http://www​.fda.gov/downloads​/BiologicsBloodVaccines​/Vaccines​/ApprovedProducts/UCM110079.pdf.

U.S. Food and Drug Administration. FDA approves rapid test for antibodies to hepatitis C virus. Jun 25, 2010. Retrieved May 12, 2011, from http://www​.fda.gov/NewsEvents​/Newsroom/PressAnnouncements​/ucm217318.htm.

U.S. Food and Drug Administration. FDA approves Victrelis for Hepatitis C. May 13, 2011. Retrieved May 12, 2011, from http://www​.fda.gov/NewsEvents​/Newsroom/PressAnnouncements​/ucm255390.htm.

U.S. Food and Drug Administration. FDA approves Incivek for hepatitis C. May 23, 2011. Retrieved May 23, 2011, from http://www​.fda.gov/NewsEvents​/Newsroom/PressAnnouncements​/ucm256299.htm.

U.S. Food and Drug Administration. Highlights of prescribing information for Incivek (telaprevir). 2011. Retrieved July 6, 2011, from http://www​.accessdata​.fda.gov/drugsatfda_docs​/label/2011/201917lbl.pdf.

U.S. Food and Drug Administration. Highlights of prescribing information for Victrelis (boceprevir). 2011. Retrieved July 6, 2011, from http://www​.accessdata​.fda.gov/drugsatfda_docs​/label/2011/202258lbl.pdf.

Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. American Journal of Gastroenterology. 2003;98(10):2281–2288. [PubMed: 14572580]

Vassilev ZP, Strauss SM, Astone JM, Friedmann PD, Des Jarlais DC. Provision of on-site medical care to patients with hepatitis C in drug treatment units. Journal of Health Care for the Poor and Underserved. 2004;15(4):663–671. [PubMed: 15531822]

Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. New England Journal of Medicine. 2007;357(17):1685–1694. [PubMed: 17947390]

Von Hippel W, Brener L, Von Hippel C. Implicit prejudice toward injecting drug users predicts intentions to change jobs among drug and alcohol nurses. Psychological Science. 2008;19(1):7–11. [PubMed: 18181783]

Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. Journal of Infectious Diseases. 2010;202(2):192–201. [PubMed: 20533878]

Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Morbidity and Mortality Weekly Report. 2008;57(RR-8):1–20. [PubMed: 18802412]

Wells R, Fenaughty A, Cagle H, Jaffe A. Hepatitis A prevalence among injection drug users. Clinical Laboratory Science. 2006;19(1):12–17. [PubMed: 16617553]

Wietzke-Braun P, Manhardt LB, Rosenberger A, Uy A, Ramadori G, Mihm S. Spontaneous elimination of hepatitis C virus infection: A retrospective study on demographic, clinical, and serological correlates. World Journal of Gastroenterology and Hepatology. 2007;13(31):4224–4229. [PMC free article: PMC4250622] [PubMed: 17696252]

Wilson MP, Castillo EM, Batey AM. Hepatitis C and depressive symptoms: Psychological and social factors matter more than liver injury. International Journal of Psychiatry in Medicine. 2010;40(2):199–215. [PubMed: 20848876]

World Health Organization. Hepatitis B fact sheet no. 204. 2009. Retrieved June 3, 2011, from http://www​.who.int/mediacentre​/factsheets/fs204/en/

Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. Journal of Family Practice. 2002;51(2):135–140. [PubMed: 11978211]

Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. “They treated me like a leper”—Stigmatization and the quality of life of patients with hepatitis C” Journal of General Internal Medicine. 2003;18(10):835–844. [PMC free article: PMC1494932] [PubMed: 14521647]